In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
August 17th, 2008 | 15 | Yes |
None
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 1.25 | 3.92 | -49.54 | 4 | 3 | 1 | 56 | 202.281 | 3 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
ALOGPS_SOLUBILITY | 1.66e+00 g/l | DrugBank-experimental |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
AKT2-2-E | Serine/threonine-protein Kinase AKT2 (cluster #2 Of 2), Eukaryotic | Eukaryotes | 5200 | 0.49 | Binding ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
AKT2_HUMAN | P31751 | Serine/threonine-protein Kinase AKT2, Human | 5200 | 0.49 | Binding ≤ 10μM |
Description | Species |
---|---|
Activation of BAD and translocation to mitochondria | |
Activation of PKB | |
AKT phosphorylates targets in the cytosol | |
AKT phosphorylates targets in the nucleus | |
AKT-mediated inactivation of FOXO1A | |
CD28 dependent PI3K/Akt signaling | |
Constitutive PI3K/AKT Signaling in Cancer | |
CTLA4 inhibitory signaling | |
deactivation of the beta-catenin transactivating complex | |
Downregulation of ERBB2:ERBB3 signaling | |
G beta:gamma signalling through PI3Kgamma | |
GPVI-mediated activation cascade | |
Inhibition of TSC complex formation by PKB | |
Negative regulation of the PI3K/AKT network | |
PDE3B signalling | |
PIP3 activates AKT signaling | |
Translocation of GLUT4 to the plasma membrane | |
VEGFR2 mediated vascular permeability |